Compounds > dmp 696
Page last updated: 2024-11-12

dmp 696

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DMP 696: a CRF(1) receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9909468
CHEMBL ID44698
SCHEMBL ID2931046
MeSH IDM0358510

Synonyms (25)

Synonym
PDSP1_001296
PDSP2_001280
cid 9909468
[8-(2,4-dichloro-phenyl)-2,7-dimethyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-(2-methoxy-1-methoxymethyl-ethyl)-amine
8-(2,4-dichlorophenyl)-n-(1,3-dimethoxypropan-2-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine
dmp696
bdbm50084875
dmp-696
CHEMBL44698 ,
8-(2,4-dichlorophenyl)-n-(1,3-dimethoxypropan-2-yl)-2,7-dimethylpyrazolo[5,1-f][1,3,5]triazin-4-amine
gtpl3499
SCHEMBL2931046
HY-12131
CS-6810
dmp 696
202578-52-7
Q27077087
pyrazolo(1,5-a)-1,3,5-triazin-4-amine, 8-(2,4-dichlorophenyl)-n-(2-methoxy-1-(methoxymethyl)ethyl)-2,7-dimethyl-
wca5scc429 ,
8-(2,4-dichlorophenyl)-n-(2-methoxy-1-(methoxymethyl)ethyl)-2,7-dimethylpyrazolo(1,5-a)-1,3,5-triazin-4-amine
unii-wca5scc429
MS-27062
8-(2,4-dichlorophenyl)-n-[2-methoxy-1-(methoxymethyl)ethyl]-2,7-dimethylpyrazolo[1,5-a]-1,3,5-triazin-4-amine
DTXSID601108708
AKOS040741653

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Selected compounds proved efficacious in an anxiety model in rats; however, pharmacokinetic properties were not optimal."( In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Ahuja, VT; Arvanitis, AG; Brenner, AB; Bronson, JJ; Combs, AP; Denhart, DJ; Deskus, JA; Ditta, JL; Grace, JE; Hartz, RA; Lelas, S; Lentz, KA; Li, J; Li, YW; Lodge, NJ; Macor, JE; Mattson, RJ; Molski, TF; Olson, RE; Rafalski, M; Schmitz, WD; Wong, H; Yue, EW; Zaczek, R, 2009)		0.35

Bioavailability

ExcerptReferenceRelevance
"0 nM) and selective CRF(1) receptor antagonist with good oral bioavailability (F = 52%) in rats and efficacy in the defensive withdrawal anxiety test in rats."( In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Ahuja, VT; Arvanitis, AG; Brenner, AB; Bronson, JJ; Combs, AP; Denhart, DJ; Deskus, JA; Ditta, JL; Grace, JE; Hartz, RA; Lelas, S; Lentz, KA; Li, J; Li, YW; Lodge, NJ; Macor, JE; Mattson, RJ; Molski, TF; Olson, RE; Rafalski, M; Schmitz, WD; Wong, H; Yue, EW; Zaczek, R, 2009)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H1 receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.03980.00151.307210.0000AID345693
Corticotropin-releasing factor receptor 1Homo sapiens (human)IC50 (µMol)0.05040.00070.06490.3400AID220022; AID308979; AID345693; AID346894
Corticotropin-releasing factor receptor 1Homo sapiens (human)Ki0.00180.00080.01020.2400AID220026; AID53810; AID53832; AID609182
Corticotropin-releasing factor receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)0.00420.00420.03030.1290AID354348
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
immune responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
activation of adenylate cyclase activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
female pregnancyCorticotropin-releasing factor receptor 1Homo sapiens (human)
parturitionCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of adenylate cyclase activity involved in G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adrenal gland developmentCorticotropin-releasing factor receptor 1Homo sapiens (human)
exploration behaviorCorticotropin-releasing factor receptor 1Homo sapiens (human)
fear responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
behavioral response to ethanolCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
general adaptation syndrome, behavioral processCorticotropin-releasing factor receptor 1Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusCorticotropin-releasing factor receptor 1Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of corticosterone secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotrophin-releasing factor receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endosomeCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
neuron projectionCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (63)

Assay IDTitleYearJournalArticle
AID442852Anxiolytic activity in Sprague-Dawley rat assessed as decrease in exit latency at 10 mg/kg, po after 60 mins by defensive withdrawal test2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing
AID26194AUCT(nM.h) value was determined in rats after intravenous dose of 5 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID28097Cmax(nM)value was determined in dogs after po dose of 1 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID30171Vss(L/kg) value was determined in rats after intravenous dose of 5 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID345693Displacement of [125I]sauvagine from human recombinant CRF1 receptor expressed in CHO cells by SPA2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.
AID24338oral pharmacokinetic parameter, Half-life period was reported in rats2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID442837Ex vivo receptor occupancy of CRF1 receptor in Sprague-Dawley rat brain parietal assessed as inhibition of [125I]sauvagine binding at 10 mg/kg, po after 90 mins by autoradiography2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing
AID25238AUC(nM.h) value was determined in rats after po dose of 5 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID26197AUCT(nM.h) value was determined in dogs after po dose of 1 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID353806Lipophilicity log P of the compound2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID193985Tested for situational anxiety in rats by measuring the latency exit from a chamber after po administration2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID30172Vss(L/kg)value was determined in dogs after intravenous dose of 1 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID220022Inhibition of corticotropin releasing factor receptor mediated increase in adenylate cyclase activity was evaluated2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID193982Tested for situational anxiety in rats by measuring the latency exit from a chamber after po administration2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID28098Cmax(nM)value was determined in rats after po dose of 5 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID353824Anxiolytic activity in rat assessed as decrease in latency to exit dark chamber at 10 mg/kg, po by defensive withdrawal test relative to untreated control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID30953t1/2 (h) value of was determined in rats after intravenous dose of 5 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID1297410Displacement of [125I]Tyr-ovine-CRF from CRF1 receptor in rat frontal cortex homogenate after 2 hrs by gamma counting analysis2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Synthesis and evaluation of carbamate and aryl ether substituted pyrazinones as corticotropin releasing factor-1 (CRF₁) receptor antagonists.
AID23874CL(L/h/kg) value was determined in rats after intravenous dose of 5 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID236297Volume distribution in rat was determined upon peroral administration2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
AID26472%bioavail value was determined in rats after po dose of 5 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID421356Displacement of [125I]ovine-CRF from CRF1 receptor in rat frontal cortex by rapid filtration technique2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID193159%binding inhibition in rat ex vivo assay after three hours2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID28520oral pharmacokinetic parameter, Maximum concentration was reported in rats2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID421376Anxiolytic activity in Sprague-Dawley rat at 3 mg/kg, po assessed as decrease in exit latency after 60 mins by defensive withdrawal test relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID23668C5min (nM) value was determined in dogs after intravenous dose of 1 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID29726Tmax(h)value was determined in dogs after po dose of 1 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID26196AUCT(nM.h) value was determined in dogs after intravenous dose of 1 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID26195AUCT(nM.h) value was determined in rats after po dose of 5 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID29727Tmax(h)value was determined in rats after po dose of 5 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID25239AUC(nM.h) value was determined in dogs after intravenous dose of 1 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID193158%binding inhibition in rat ex vivo assay after one hour2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID29840oral pharmacokinetic parameter, Oral bioavailability was reported in dogs2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID220026Compound was tested for the binding affinity to human corticotropin releasing factor receptor2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID308979Displacement of [125I]CRF from human recombinant CRF1 receptor expressed in CHO cell membrane2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Novel substituted tetrahydrotriazaacenaphthylene derivatives as potent CRF1 receptor antagonists.
AID354385Anxiolytic-like activity in Sprague-Dawley rat assessed as decrease in latency to exit dark chamber at 10 mg/kg, po measured after 1 hr by defensive withdrawal test relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
AID30947oral pharmacokinetic parameter, Half-life period was reported in dogs2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID353822Anxiolytic activity in rat assessed as increase in time spent on open arm at 18 mg/kg, po by elevated plus-maze test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID193986Tested for situational anxiety in rats by measuring the latency exit from a chamber after po administration2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID353821Solubility in dilute HCl at pH 2.32009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID30136CL (L/h/kg) value was determined in dogs after intravenous dose of 1 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID15496C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID25240AUC(nM.h) value was determined in dogs after po dose of 1 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID609182Antagonist activity at human CRF-1 receptor2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
AID28519oral pharmacokinetic parameter, Maximum concentration was reported in dogs2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID421375Anxiolytic activity in Sprague-Dawley rat at 10 mg/kg, po assessed as decrease in exit latency after 60 mins by defensive withdrawal test relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID30948oral pharmacokinetic parameter, Half-life period was reported in rats2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID353817Aqueous solubility at pH 7.42009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID237197Terminal half life in rat was determined upon oral administration2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
AID243181Displacement of [125I]o-CRF from recombinant human CRF receptors expressed in Chinese Hamster Ovary (CHO) cell membranes2005Bioorganic & medicinal chemistry letters, Aug-15, Volume: 15, Issue:16
Substituted tetraazaacenaphthylenes as potent CRF1 receptor antagonists for the treatment of depression and anxiety.
AID30956t1/2 (h) value was determined in dogs after po dose of 1 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID53810Compound was tested for the binding affinity to human corticotropin releasing factor receptor2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID26473% bioavailability value was determined in dogs after po dose of 1 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID354383Anxiolytic-like activity in Sprague-Dawley rat assessed as increase in time spent in open arms at 18 mg/kg, po measured after 1 hr by elevated plus maze test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
AID346894Displacement of [125I]sauvagine from human recombinant CRF1 receptor expressed in CHO cells2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.
AID193983Tested for situational anxiety in rats by measuring the latency exit from a chamber after po administration2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID29841oral pharmacokinetic parameter, Oral bioavailability was reported in rats2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID30954t1/2 (h) value was determined in rats after po dose of 5 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID53832Displacement of [125I]-tyrosine-ovine-CRF from human Corticotropin releasing factor receptor 12000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID354348Displacement of [125I]Tyr0-ovine CRF from CRF1 receptor in rat cortical membrane by gamma counting2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
AID353807Aqueous solubility at pH 72009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
AID30955t1/2 (h) value was determined in dogs after intravenous dose of 1 mg/kg2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
AID1345736Human CRF1 receptor (Corticotropin-releasing factor receptors)2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's26 (83.87)29.6817
2010's5 (16.13)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.05 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index5.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (93.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
alpha-methyltyrosine methyl ester
alpha-methyltyrosine methyl ester: RN given refers to parent cpd		2.0410
alprazolam
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.		2.0210organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
chlordiazepoxide
Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.		3.470benzodiazepine
desipramine
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.		2.0210dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
fluoxetine
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.		2.4320(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
furosemide
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.		2.0510chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
clorgyline
Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.. clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.		2.0210aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound		antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor
fenclonine
Fenclonine: A selective and irreversible inhibitor of tryptophan hydroxylase, a rate-limiting enzyme in the biosynthesis of serotonin (5-HYDROXYTRYPTAMINE). Fenclonine acts pharmacologically to deplete endogenous levels of serotonin.		2.0410phenylalanine derivative
corticosterone
[no description available]		2.482011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
carbachol
Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.		2.0510ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.4220pyrrole;
secondary amine
tranylcypromine
Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.		2.02102-phenylcyclopropan-1-amine
4-chlorophenylalanine methyl ester
4-chlorophenylalanine methyl ester: RN given refers to parent cpd without isomeric designation		2.0410
selegiline
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.		2.0210selegiline;
terminal acetylenic compound		geroprotector
paroxetine
Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.		2.0210aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
reboxetine
Reboxetine: A morpholine derivative that is a selective and potent noradrenaline reuptake inhibitor; it is used in the treatment of DEPRESSIVE DISORDER.		2.0210aromatic ether
atropine
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.		2.0510
nbi 27914
[no description available]		3.8130dialkylarylamine;
tertiary amino compound
antalarmin
antalarmin : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidin-4-amine which is substituted by methyl groups at positions 2, 5, and 6, by a mesityl group at position 7, and in which the amino substituent at position 4 has been substituted by ethyl and butyl groups. It is an antagonist of corticotropin-releasing factor 1 (CRF-1) receptors (Ki = 1 nM).		4.0340pyrrolopyrimidine;
tertiary amino compound		corticotropin-releasing factor receptor antagonist
arginine vasopressin
Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.		2.0510vasopressincardiovascular drug;
hematologic agent;
mitogen
cp 154526
[no description available]		2.9540
vofopitant
[no description available]		2.0310
r 121919
[no description available]		2.9540
cra1000
CRA1000: a non-peptidic corticotropin-releasing hormone receptor type 1 antagonist		3.110
pexacerfont
[no description available]		2.4620pyrazolopyridine
4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)pyrazolo(1,5-a)pyrimidine
4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)pyrazolo(1,5-a)pyrimidine: an hCRF(1) antagonist; structure in first source		4.5440
nbi-34041
NBI-34041: high-affinity CRF1 (corticotropin-releasing factor receptor 1) receptor antagonist for attenuating elevated stress response		2.4420
cp 154526
CP 154526: structure in first source		3.830
sauvagine
sauvagine: isolated from skin of South American hylid frog, Phyllomedusa sauvagei; has hypotensive & antidiuretic effect; potent stimulating action on secretion of ACTH & corticosterone; inhibitory effect on secretion of PRL, GH, & TSH; consists of straight chain of 40 amino acid residues		2.7130
astressin
astressin : A 30-membered homodetic cyclic peptide comprising the sequence D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 cyclised by an amide bridge, formed by condensation of the side-chain carboxy group of the Glu residue at position 19 and the side-chain amino group of the Lys residue at position 22.		2.4220homodetic cyclic peptide;
polypeptide		corticotropin-releasing factor receptor antagonist;
neuroprotective agent
bms 665053
BMS 665053: structure in first source		2.4520
piperidines
Piperidines: A family of hexahydropyridines.		2.0310
methylcellulose
Methylcellulose: Methylester of cellulose. Methylcellulose is used as an emulsifying and suspending agent in cosmetics, pharmaceutics and the chemical industry. It is used therapeutically as a bulk laxative.		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.7230
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		04.0450
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		02.0210
Genetic Predisposition
[description not available]		02.110
Chronic Illness
[description not available]		02.0510
Allodynia
[description not available]		02.0510
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.0510
Inadequate Sleep
[description not available]		02.0510
Ataxia
Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.		02.0110
Drug Withdrawal Symptoms
[description not available]		02.0110
Substance Withdrawal Syndrome
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.		02.0110
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.0110